Andrew K. Godwin
A5033625395- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Gastrointestinal Tumor Research and Treatment
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- DNA Repair Mechanisms
- Cancer Cells and Metastasis
- Nutrition, Genetics, and Disease
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Genetic Associations and Epidemiology
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Genetic factors in colorectal cancer
- Extracellular vesicles in disease
- Gastrointestinal disorders and treatments
- Estrogen and related hormone effects
- Cancer-related Molecular Pathways
- RNA Research and Splicing
- PI3K/AKT/mTOR signaling in cancer
University of Kansas Medical Center
2016-2025
The University of Kansas Cancer Center
2016-2025
The University of Melbourne
2022-2025
University of Kansas
2011-2024
University of Kentucky
2009-2024
Beijing Hospital
2024
Augusta University Health
2024
University of California, Irvine
2024
Fox Chase Cancer Center
2010-2023
University Medical Center
2011-2023
The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen only a subset of patients. This study was conducted to identify markers that associated with disease control patients treated cetuximab.One hundred ten metastatic colorectal cancer were enrolled onto monotherapy trial. Transcriptional profiling on RNA from mandatory pretreatment biopsies genes whose expression correlates best clinical responses....
Exposure of human ovarian tumor cell lines to cisplatin led development that exhibited increasing degrees drug resistance, which were closely correlated with increase the levels cellular glutathione. Cell obtained showed 30- 1000-fold increases in resistance; these cells also had strikingly increased (13- 50-fold) glutathione as compared drug-sensitive origin. These resistance and are substantially greater than previously reported. Very high was associated enhanced expression mRNAs for...
We isolated cDNA clones containing the entire coding region of putative oncogene AKT2. Sequence analysis and in vitro translation demonstrated that AKT2 encodes a 56-kDa protein with homology to serine/threonine kinases; moreover, this contains Src 2-like domain. was shown be amplified overexpressed 2 8 ovarian carcinoma cell lines 15 primary tumors. mapped chromosome 19q13.1-q13.2 by fluorescence situ hybridization. In two exhibiting amplification AKT2, sequences were localized within...
Specimen collection is an integral component of clinical research. Specimens from subjects with various stages cancers or other conditions, as well those without disease, are critical tools in the hunt for biomarkers, predictors, tests that will detect serious diseases earlier more readily than currently possible. Analytic methodologies evolve quickly. Access to high-quality specimens, collected and handled standardized ways minimize potential bias confounding factors, key "bench bedside"...
MicroRNAs (miRNA) are a recently discovered class of noncoding RNAs that negatively regulate gene expression. Recent evidence indicates miRNAs may play an important role in cancer. However, the mechanism their deregulation neoplastic transformation has only begun to be understood. To elucidate tumor suppressor p53 regulation miRNAs, we have analyzed changes miRNA microarray expression profile immediately after conditional inactivation primary mouse ovarian surface epithelium cells. Among...
Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing patients. We assessed frequency mutations 17 predisposition genes, including BRCA1 and BRCA2, a large cohort patients with triple-negative (TNBC) unselected family history or ovarian determine utility those TNBC. Patients Methods TNBC (N = 1,824) were recruited through 12 studies, was sequenced identify mutations. Results Deleterious identified 14.6%...
Abstract Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets mutation carriers should allow further tumor characterization. Methods: We used data from 4,325 2,568 to analyze the pathology invasive breast, ovarian, contralateral cancers. Results: There was strong evidence proportion estrogen receptor (ER)-negative decreased with age at diagnosis among (P-trend = 1.2 × 10−5), but increased BRCA2, 6.8 10−6)....
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization 110 tumors 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, gender. Proteomic phosphoproteomic data illuminated downstream copy number aberrations, somatic...
Developing blood-based tests is appealing for non-invasive disease diagnosis, especially when biopsy difficult, costly, and sometimes not even an option. Tumor-derived exosomes have attracted increasing interest in cancer diagnosis monitoring of treatment response. However, the biology clinical value remains largely unknown due part to current technical challenges rapid isolation, molecular classification comprehensive analysis exosomes. Here we developed a new microfluidic approach...
Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with 1,839 cancer), replication in an additional sample 2,646 carriers. We identified novel risk modifier locus at 1q32 for (rs2290854, P = 2.7×10−8, HR 1.14, 95% CI: 1.09–1.20). In addition, two loci: 17q21.31 (rs17631303, 1.4×10−8, 1.27, 1.17–1.38) 4q32.3 (rs4691139,...
On the basis of multidimensional and comprehensive molecular characterization (including DNA methalylation copy number, RNA, protein expression), we classified 894 renal cell carcinomas (RCCs) various histologic types into nine major genomic subtypes. Site origin within nephron was one determinant in classification, reflecting differences among clear cell, chromophobe, papillary RCC. Widespread changes associated with TFE3 gene fusion or chromatin modifier genes were present a specific...
The miR-34 family is directly transactivated by tumor suppressor p53, which frequently mutated in human epithelial ovarian cancer (EOC). We hypothesized that expression would be decreased EOC and reconstituted might reduce cell proliferation invasion of cells.miR-34 was determined quantitative reverse transcription-PCR situ hybridization a panel 83 samples. Functional characterization accomplished reconstitution cells with synthetic pre-miR molecules followed determining changes...
Abstract Establishing a cancer screening biomarker's intended performance requires “phase III” specimens obtained in asymptomatic individuals before clinical diagnosis rather than II” from symptomatic at diagnosis. We used the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian biomarkers previously assessed phase II sets. Phase 180 cases 660 benign disease or general population controls were assembled four Early Detection Research Network Specialized...